Peritoneal metastases (PM) from colorectal cancer (CRC) were traditionally associated with
bad prognosis. Only recently, cytoreductive surgery (CRS) with hyperthermic intraperitoneal …

Answer questions and earn CME/CNE Until recently, a diagnosis of peritoneal
carcinomatosis was uniformly accompanied by a grim prognosis that was typically measured …

Objective: To improve patient selection for cytoreductive surgery (CRS) and hyperthermic
intraperitoneal chemotherapy (HIPEC) by evaluating various preoperatively assessable …

Objective: Synchronic colorectal peritoneal carcinomatosis (SCRPC) was recognized as a
predictor of poor prognosis. The aim of this study was to investigate the role of neutrophil-to …

Background KRAS and BRAF mutations are prognostic and predictive tools in metastatic
colorectal cancer, but little is known about their prognostic value in patients scheduled for …

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a
viable option for selected patients with peritoneal metastases (PM) from colorectal origin …

Opinion statement Peritoneal metastases (PM) are common in advanced-stage colorectal
cancer (CRC) patients representing the second most common metastatic site of CRC. In the …

Aim Peritoneal metastases from colorectal cancer confer the worst survival among all
metastatic sites. The adoption of cytoreductive surgery (CRS) with hyperthermic …

Peritoneal carcinomatosis (PTC) represents advanced malignant disease and has generally
been associated with a grim prognosis. Peritoneal surface malignancy is often the major …

Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of
metastatic disease progression remains difficult to treat with systemic therapies due to poor …